Journals / Turkish Journal of Medical Sciences / 2012 / Cilt: 42 - Sayı: 5

Effects of Ankaferd hemostat on the synovial fluid of patients with osteoarthritis

Pages
768–772
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This observation, together with hemostatic and wound healing properties of ABS, might provide an important starting point for testing its actions on distinct hemorrhagic, neoplastic, or inflammatory joint disorders.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent with antiinfective, wound healing, and antineoplastic properties.
📊
Key Findings & Data:Materials and methods: Synovial fluid samples were obtained from 10 patients with osteoarthritis (5 women, 5 men; mean age 57.6 ± 11.2 years).
💡
Conclusion & Impact:This observation, together with hemostatic and wound healing properties of ABS, might provide an important starting point for testing its actions on distinct hemorrhagic, neoplastic, or inflammatory joint disorders.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Ankaferd Blood Stopper (ABS) · synovial effusion · osteoarthritis

Abstract

Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent with antiinfective, wound healing, and antineoplastic properties. In this study, we evaluated the macroscopic and biochemical effects of ABS in the joint fluid of patients with osteoarthritis. Materials and methods: Synovial fluid samples were obtained from 10 patients with osteoarthritis (5 women, 5 men; mean age 57.6 ± 11.2 years). From each patient, 4 mL of synovial fluid was drawn and put into 2 different serum separator tubes, and 1 mL of ABS was added to the first sample and 1 mL of 0.9% saline was added to the second sample. Macroscopic evaluation and biochemical analyses for glucose, protein, albumin, and lactate dehydrogenase (LDH) were performed. Results: The addition of ABS into synovial fluid revealed a rapid and apparent reaction resulting in dense coagulation within seconds in all of the samples. No reaction was observed in the saline group. Total protein, albumin, globulin, and LDH levels significantly decreased in the ABS group, while glucose levels remained unchanged. Conclusion: ABS can work in the synovial fluid, causes rapid frozen gel-like solidification, and decreases the protein component of the synovial fluid. This observation, together with hemostatic and wound healing properties of ABS, might provide an important starting point for testing its actions on distinct hemorrhagic, neoplastic, or inflammatory joint disorders.

Özet

Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent with antiinfective, wound healing, and antineoplastic properties. In this study, we evaluated the macroscopic and biochemical effects of ABS in the joint fluid of patients with osteoarthritis. Materials and methods: Synovial fluid samples were obtained from 10 patients with osteoarthritis (5 women, 5 men; mean age 57.6 ± 11.2 years). From each patient, 4 mL of synovial fluid was drawn and put into 2 different serum separator tubes, and 1 mL of ABS was added to the first sample and 1 mL of 0.9% saline was added to the second sample. Macroscopic evaluation and biochemical analyses for glucose, protein, albumin, and lactate dehydrogenase (LDH) were performed. Results: The addition of ABS into synovial fluid revealed a rapid and apparent reaction resulting in dense coagulation within seconds in all of the samples. No reaction was observed in the saline group. Total protein, albumin, globulin, and LDH levels significantly decreased in the ABS group, while glucose levels remained unchanged. Conclusion: ABS can work in the synovial fluid, causes rapid frozen gel-like solidification, and decreases the protein component of the synovial fluid. This observation, together with hemostatic and wound healing properties of ABS, might provide an important starting point for testing its actions on distinct hemorrhagic, neoplastic, or inflammatory joint disorders.

🔖

Cite This Article

DEMİRAĞ, M. D., ÖZTÜRK, M. A., KOÇAK, Z. T., HAZNEDAROĞLU, İ. C. (2022). Effects of Ankaferd hemostat on the synovial fluid of patients with osteoarthritis. Turkish Journal of Medical Sciences, Cilt: 42 - Sayı: 5, 768–772. https://ajindex.com/articles/611290

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic eff ects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15: 329-36
  2. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, Bilgili H, Goker H, Kosar A et al. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic eff ects of Ankaferd Blood Stopper. Clin Appl Th romb Hemost 2010; 16: 446-53
  3. Haznedaroglu IC. Molecular basis of the pleiotropic eff ects of Ankaferd Blood Stopper. IUBMB Life 2009; 61: 290
  4. Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y et al. Haemostatic actions of the folkloric medicinal plant extract, Ankaferd blood stopper. J Int Med Res 2008; 36: 163-70
  5. Bilgili H, Kosar A, Kurt M, Onal IK, Goker H, Captug O et al. Hemostatic effi cacy of Ankaferd Blood Stopper in a swine bleeding model. Med Princ Pract 2009; 18: 165-9
  6. Huri E, Akgül KT, Yücel MO, Astarcı HM, Üstün H, Germiyanoğlu RC. Th e second step in vitro trial of Ankaferd® Bloodstopper®: comparison with other hemostatic agents. Turk J Med Sci 2011; 41: 7-15
  7. Tasdelen Fisgin M, Tanrıverdi Cayci Y, Coban AY, Ozatli D, Tanyel E, Durupinar B et al. Antimicrobial activity of plant extract Ankaferd Blood Stopper. Fitoterapia 2009; 80: 48-50
  8. Akkoc N, Akcelik M, Haznedaroglu I, Goker H, Aksu S, Kirazli S et al. In vitro antibacterial activities of Ankaferd Blood Stopper. Int J Lab Hematol 2008; 30:95
  9. Isler SC, Demircan S, Cakarer S, Cebi Z, Keskin C, Soluk M et al. Eff ects of folk medicinal plant extract Ankaferd Blood Stopper on early bone healing. J Appl Oral Sci 2010; 18: 409-14
  10. Coban YK, Ozerol E, Tanber K, Erbatur S, Aytekin AH, Fırat C. Hemeostatic effi cacy of Ankaferd aft er excision of full thickness burns: a comparative experimental study in rats. Surgical Science 2011; 2: 16-21
  11. Göker H, Çetinkaya D, Kılıç E, Haznedaroğlu IC, Kirazlı S, Fırat H. Anti-cancer activity of Ankaferd blood stopper on osteosarcom (SAOS-2) cell lines in vitro. In: Haznedaroğlu I.C. GH, Özdemir O, Koşar A, Fırat H, editors. Ankaferd: Scientifi c perspectives and basic-clinical data. İstanbul: Naviga Publications; 2008. p.109
  12. Göker H, Kılıc E, Çetinkaya D, Haznedaroğlu IC, Kirazlı S, Fırat H. Anti-cancer activity of Ankaferd on human colon cancer (CACO-2) in vitro. In: Haznedaroğlu IC, Göker H, Özdemir O et al., editors. Ankaferd: Scientifi c Perspectives and Basic-Clinical Data. İstanbul: Naviga Publications; 2008. p.108
  13. Karaman